Qubit Pharmaceuticals is a brand-new international company, spun off from CNAM, CNRS, University of Texas at Austin, Sorbonne University and Washington University, and based in Paris. Qubit Pharmaceuticals builds upon more than 20 years of R&D awarded by the most prestigious prizes.
Qubit Pharmaceuticals is supported by Quantonation, a leading investment fund in quantum technologies in its mission to revolutionize the way drugs are developed and provide safer and more efficient drugs faster.
Qubit Pharmaceuticals is laureate of the EIT health headstart program and incubated at Paris Biotech Santé.
Pr Jay Ponder
Prof. Ponder’s research has a long-standing emphasis on the development and application of accurate molecular mechanics models for biomolecular structural analysis. Over the past several years his group has produced the
AMOEBA polarizable atomic multipole force field; one of the most accurate classical protein models currently available. Current applications of AMOEBA in the Ponder group include ab initio prediction of peptide and small molecule crystal structures, investigation of hydrophobic effects in liquid mixtures, and a series of problems related to drug design for particular systems of current biomedical importance. Of particular interest is the calculation of binding free energies for protein-ligand and host-guest systems. The force fields being developed for biomolecules are available through the Tinker and Tinker-HP software for CPU and GPU. In addition, by integrating computational and experimental approaches, he has studied protein-DNA assemblies in autoimmunity, biomaterials for tissue engineering, and novel inhibitors for protein kinases critical in cell signaling.
Pr Pengyu Ren
Professor Ren is E.C.H Bantel Professor for Professional Practice at UT Austin, and Fellow of American Institute for Medical and Biological Engineering. Dr. Ren is an author of over 100 publications, served as lead PI on several NIH and NSF projects. Ren lab’s research focuses on understanding the physical driving forces underlying biomolecular structures, dynamics, and interactions, and developing accurately physical models to engineer functional molecules and materials in silico. Along with Prof. Ponder, he was the first to develop an advanced electrostatic model for biomolecular simulations that incorporated atomic multipoles and many-body polarization effects and to demonstrate the accuracy of such models in prediction of protein-ligand recognition. Currently, he is extending AMOEBA to the next generation AMOEBA+ model with significantly improved functional forms and accuracy but at a reduced computational cost. The models and algorithms he developed are available through Tinker and Tinker-HP software for CPU and GPU computing. In addition, by integrating computational and experimental approaches, his lab has studied protein-DNA assemblies in autoimmunity, biomaterials for tissue engineering, and novel inhibitors targeting protein kinases in cell signaling.
Pr J.-P. Piquemal, CSO
Professor Piquemal is the prestigious winner of the 2018 Atos – Joseph Fourier Prize in High-Performance Computing as well as a winner of the 2018 European Research Council Synergy Grant for his work on Extreme-scale Mathematically-based Computational Chemistry (€10M). He is also a Member of the Institut Universitaire de France, and is currently the director for the Laboratoire de Chimie Théorique at Sorbonne Université . He is a recipient of the Wiley – International Journal of Quantum Chemistry Young Investigator award. His research is devoted to theoretical chemistry, applied mathematics, software development innovations in multiscale quantum chemistry for large systems, new generation polarizable force fields, and quantum chemical topology. He is the lead developer of the Tinker-HP software, a massively parallel version of Tinker allowing for fast molecular simulations on new-generation supercomputers and GPUs cards.
Dr Louis Largardère
Dr. Lagardere has been trained in Applied Mathematics at the Ecole Nationale des Ponts et Chaussees and holds a Ph.D. in theoretical chemistry from Sorbonne University. He is a co-recipient of the Atos Joseph Fourier 2018. Since 2016, he holds a permanent Research Engineer position in Paris and works as the lead programmer for the Tinker-HP project. His expertise lies in high-performance computing (C3I GENCI fellow), theoretical chemistry and applied mathematics. He is the author of more than 30 scientific papers and leads the engineering team in the EMC2 European project.
Pr Matthieu Montes
Prof Matthieu Montes, leads the molecular modeling and drug design team of the GBCM lab at Conservatoire National des Arts et Métiers, Paris, France. His research interests include molecular modeling, drug discovery and design, interactive visualization and simulation methods, and computational geometry. He is a recipient of the prestigious SCT award for Young Investigators in Medicinal Chemistry. Since 2014, he is a fellow of the European Research Council for his work on the ViDOCK project focused on applying mathematics and computer graphics methods in computational biology and chemistry (€1.5M). He is a co-author of 50 publications and co-inventor of 7 patents for therapeutic products in cancer and inflammation
Chris Ho, MD PhD
Dr. Ho was an early pioneer in the development of computer-aided drug design (CADD) techniques and software, publishing numerous algorithms to facilitate molecular visualization, virtual screening, and chemical database design, which became incorporated into successful commercial packages. The experience of consulting with numerous pharmaceutical companies, including Monsanto, Fisons, Parke Davis, Pharmacia, Pfizer, and Dupont, led to the development of two highly successful commercial packages, RACHEL and CHARLIE, which were published through Tripos, Inc. (now part of Certara). These products help medicinal chemists refine weak binding leads to much more potent drugs and were licensed to over forty major pharmaceutical companies worldwide prior to the sale of Tripos to private investors in 2009
Christophe Jurczak, PhD
Dr Jurczak is founding partner at Quantonation, the first Venture Capital fund dedicated to quantum technologies and Deep Physics. He has led several investments in quantum hardware and software startups, and is chairman of Pasqal and board Member of Kets. Prior to Quantonation, he was head of business development at QC Ware, a Silicon Valley based leading quantum software developer, and has managed before that several companies in the Energy sector in Europe and in the US. Dr Jurczak is also the co-founder of Le Lab Quantique, a not for profit dedicated to the emerging quantum industry.
Robert Marino, PhD
Robert has more than 10 years of experience in business development, startup creation and tech transfer. He started by helping Fortune 500 companies with their Open Innovation strategy, in particular by supporting them in their collaborations with startups. He then moved to the Fondation Pierre Gilles de Gennes pour la Recherche, he was responsible for industrial partnerships between startups/SMEs in biotech/medtech and laboratories. Then he cofounded idfinnov a TTO with a 60m+ POC fund and became Manager of the Engineering, IT & Materials Sciences Business Unit, he has audited and supported more than 150 projects per year. He oversaw 40 investments in AI, Sensors, medtech, Quantum Computing, nanotechnologies.
Last, Robert cofounded Deeptech Founders, a Paris Based accelerator helping more than 100 teams to launch their business since 2019. The 12 first startups created already raised €30m+ and hired 100 people.